MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells - Wikidata - awgldk - TriplyDB

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

http://www.wikidata.org/entity/Q34607094

about

tRNA binding to antitumor drug doxorubicin and its analogue Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis.Mesothelin's minimal MUC16 binding moiety converts TR3 into a potent cancer therapeutic via hierarchical binding events at the plasma membrane TRAIL combinations: The new 'trail' for cancer therapy (Review).Alternative splicing as a biomarker and potential target for drug discovery.MADD is a downstream target of PTEN in triggering apoptosis.Loss of Function of KCNC1 is associated with intellectual disability without seizures.

P2860

Q28534958-AE276A15-2005-42D0-982E-33DED04FF278 Q37246966-7E1D7CC2-3654-4865-AFFE-970AD498DBA6 Q37327815-822F5B69-C574-41EF-9AB1-D31C08AF01E2 Q37719944-7F61D152-0EB6-4B9B-839B-10C13D121156 Q38527484-630C67CF-788C-44A7-A971-E128E4958B75 Q39095766-D970FAF3-F099-4332-96E2-DD62D9E473CB Q51158767-6892F8DB-31F4-4A3B-A307-2067B99CB5C8

P2860

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

http://www.wikidata.org/entity/Q34607094

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

@ast

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

@en

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

@nl

type

label

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

@ast

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

@en

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

@nl

prefLabel

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

@ast

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

@en

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

@nl

P1433

Q34607094-F1619016-881E-4584-A61C-4AE999C3E391

P1476

Q34607094-4094BC06-5B8C-44BA-8EE0-B770357566E7

P2093

Q34607094-14243CA0-C5CE-496A-BDF5-8B7438CCCD0F

Q34607094-30D285CE-31B7-4546-BC35-5E7D4869EC37

Q34607094-3A6E1193-9111-476F-BEF4-86E7A59511BC

Q34607094-604D7B16-7018-4CB8-9441-F9E301A5E4B5

Q34607094-622CEF33-B5DE-43F3-BBC8-CBEF03026AC6

Q34607094-62EB9F14-2C83-4752-94EF-5EEB75A87766

Q34607094-87DC51CE-89D4-43F2-9270-B24AD9344F15

Q34607094-9EC6B87E-E899-4815-BCC6-018B9F477E5F

Q34607094-B39A8FBC-1E51-4454-9EF9-F93C55403251

Q34607094-C7D5BA1F-C4E4-4F73-8B37-535555828895

P2860

Q34607094-0704EC6F-E357-4EFE-84FF-52A0EF32D76E

Q34607094-1A3C4C81-A7FD-4C1D-90A2-8FDBEA908DEB

Q34607094-1AB5FBD2-AF27-4D42-B1F5-B6F7C3E92119

Q34607094-21BA107C-915A-4BB0-A8E6-701A46A860EF

Q34607094-33918BAC-F16C-4EAF-A872-5C139669B97C

Q34607094-33D30EA3-9229-4961-9F45-2B6963A50493

Q34607094-3F6F43EF-7366-4B9D-924B-BA11CDD2A529

Q34607094-434BBD4B-8DE3-4E4E-B08F-4F916E7CB874

Q34607094-453D91A2-F1B3-45F3-AC78-7A0E3CBD69C3

Q34607094-607ABB6E-A8B4-4B54-A0AF-BC5EC233CB8B

P304

Q34607094-F62BA9C1-6212-45FB-A329-619BA61A473E

P31

Q34607094-10A1DEBA-C83F-4E3F-9352-3756DEAB3E76

P356

Q34607094-E7D0CB70-0ED2-453F-8175-56BE4311BED5

P407

Q34607094-DD8CD758-6256-4079-8926-D21AA54D6FF3

P433

Q34607094-98189FD0-D7F7-49E7-B9AB-029583E02EDE

P478

Q34607094-1B417EFB-D756-4FFD-914C-3FEA93963573

P577

Q34607094-AE97FA73-8CF4-493F-BCED-8BBF3EA0F209

P5875

Q34607094-E67D01CE-4070-4EEA-ADAD-62D668A491E2

P698

Q34607094-4452C658-A837-4040-8EDC-1436361D2B3A

P932

Q34607094-D64E6416-224E-4A93-9C8A-D306DA82CD10

P356

JOURNAL.PONE.0056817

P1433

P1476

MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells

@en

P2093

Ajay V Maker

http://www.w3.org/2001/XMLSchema#string

Andrea Turner

http://www.w3.org/2001/XMLSchema#string

Bellur S Prabhakar

http://www.w3.org/2001/XMLSchema#string

Elizabeth Louise Wiley

http://www.w3.org/2001/XMLSchema#string

Konstantin Christov

http://www.w3.org/2001/XMLSchema#string

Lakshmy Ganesh

http://www.w3.org/2001/XMLSchema#string

Liang-Cheng Li

http://www.w3.org/2001/XMLSchema#string

Lixia Qian

http://www.w3.org/2001/XMLSchema#string

Peifeng Li

http://www.w3.org/2001/XMLSchema#string

Prasad Kanteti

http://www.w3.org/2001/XMLSchema#string

P2860

Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor alpha-induced apoptosis and activation of caspase-8 and -3

The receptor for the cytotoxic ligand TRAIL

A novel association between p130Cas and resistance to the chemotherapeutic drug adriamycin in human breast cancer cells.

Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells.

TRAIL receptor-2 signals apoptosis through FADD and caspase-8

Induction of marked apoptosis in mammalian cancer cell lines by antisense DNA treatment to abolish expression of DENN (differentially expressed in normal and neoplastic cells)

IG20, a MADD splice variant, increases cell susceptibility to gamma-irradiation and induces soluble mediators that suppress tumor cell growth

IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs

Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL

IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC

P304

e56817

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0056817

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235778547

http://www.w3.org/2001/XMLSchema#string

P698

23457619

http://www.w3.org/2001/XMLSchema#string

P932

3574069

http://www.w3.org/2001/XMLSchema#string